Lee Silverman voice treatment versus standard NHS speech and language therapy versus control in Parkinson’s disease (PD COMM pilot): study protocol for a randomized controlled trial

Trials

Carl Clarke⁷  Gina Sands⁴  Debbie Kelly⁴  Smitaa Patel²  Keith Wheatley³  Sue Jowett¹  Francis Dowling²  Helen Roberts⁸  Ramilla Patel⁵  Natalie Ives²  Marian C Brady⁹  Caroline Rick²  Christina H Smith⁶  Catherine M Sackley⁴ 

[1] School of Health and Population Sciences, University of Birmingham, University Road West, Birmingham B15 2TT, UK;Birmingham Clinical Trials Unit (BCTU), University of Birmingham, Hospital Drive, Birmingham B15 2TT, UK;Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Hospital Drive, Birmingham B15 2TT, UK;School of Rehabilitation Sciences, University of East Anglia, Earlham Road, Norwich NR4 7TJ, UK;Parkinson’s UK West Midlands Regional Branch, Head office, 215 Vauxhall Bridge Road, London SW1V 1EJ, UK;Division of Psychology and Language Science, Faculty of Brain Sciences, University College London, Wakefield Street, London WC1N 1PF, UK;School of Clinical and Experimental Medicine, University of Birmingham, Vincent Drive, Birmingham B15 2TT, UK;Faculty of Medicine, University of Southampton, University Road, Southampton SO17 1BJ, UK;Nursing, Midwifery and Allied Health Professions Research Unit, Glasgow Caledonian University, Cowcaddens Road, Glasgow G4 0BA, UK

关键词: LSVT®;    Randomized controlled trial;    Lee Silverman Voice Treatment;    Speech and language therapy;    Parkinson’s disease;   

Others  :  805165
DOI  :  10.1186/1745-6215-15-213

 received in 2014-02-17, accepted in 2014-05-20,  发布年份 2014

【 摘 要 】

Background

Parkinson’s disease is a common movement disorder affecting approximately 127,000 people in the UK, with an estimated two thirds having speech-related problems. Currently there is no preferred approach to speech and language therapy within the NHS and there is little evidence for the effectiveness of standard NHS therapy or Lee Silverman voice treatment. This trial aims to investigate the feasibility and acceptability of randomizing people with Parkinson’s disease-related speech or voice problems to Lee Silverman voice treatment or standard speech and language therapy compared to a no-intervention control.

Methods/Design

The PD COMM pilot is a three arm, assessor-blinded, randomized controlled trial. Randomization will be computer-generated with participants randomized at a ratio of 1:1:1. Participants randomized to intervention arms will be immediately referred to the appropriate speech and language therapist. The target population are patients with a confirmed diagnosis of idiopathic Parkinson’s disease who have problems with their speech or voice. The Lee Silverman voice treatment intervention group will receive the standard regime of 16 sessions between 50 and 60 minutes in length over four weeks, with extra home practice. The standard speech and language therapy intervention group will receive a dose determined by patients’ individual needs, but not exceeding eight weeks of treatment. The control group will receive standard care with no speech and language therapy input for at least six months post-randomization. Outcomes will be assessed at baseline (pre-randomization) and post- randomization at three, six, and 12 months. The outcome measures include patient-reported voice measures, quality of life, resource use, and assessor-rated speech recordings. The recruitment aim is at least 60 participants over 21 months from 11 sites, equating to at least 20 participants in each arm of the trial. This trial is ongoing and recruitment commenced in May 2012.

Discussion

This study will provide information on the feasibility and acceptability of randomizing participants to different speech and language therapies or control/deferred treatment. The findings relating to recruitment, treatment compliance, outcome measures, and effect size will inform a future phase III randomized controlled trial.

Trial registration

International Standard Randomised Controlled Trial Number Register: ISRCTN75223808 registered 22 March 2012.

【 授权许可】

   
2014 Sackley et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Parkinson’s UK: Parkinson’s prevalence in the United Kingdom. 2009. [http://www.parkinsons.org.uk/sites/default/files/parkinsonsprevalenceuk_0.pdf webcite]
• [2]Perez-Lloret S, Negre-Pages L, Ojero-Senard A, Damier P, Destee A, Tison F, Merello M, Rascol O: Oro-buccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinson’s disease: preliminary analysis from the French COPARK cohort. Eur J Neurol 2012, 19:28-37.
• [3]Hartelius L, Svensson P: Speech and swallowing symptoms associated with Parkinson’s disease and multiple sclerosis: a survey. Folia Phoniatr Logop 1994, 46:9-17.
• [4]Miller N, Noble E, Jones D, Burn D: Life with communication changes in Parkinson’s disease. Age Ageing 2006, 35:235-239.
• [5]Herd CP, Tomlinson CL, Deane KH, Brady MC, Smith CH, Sackley CM, Clarke CE: Speech and language therapy versus placebo or no intervention for speech problems in Parkinson’s disease. Cochrane Db Syst Rev 2012., 8CD002812
• [6]The National Collaborating Centre for Chronic Conditions: Parkinson’s disease: national clinical guideline for diagnosis and management in primary and secondary care. London, UK: Royal College of Physicians; 2006.
• [7]Parkinson’s UK: Life with Parkinson’s today – room for improvement. [http://www.parkinsons.org.uk/content/life-parkinsons-today-room-improvement webcite]
• [8]Miller N, Deane KH, Jones D, Noble E, Gibb C: National survey of speech and language therapy provision for people with Parkinson’s disease in the United Kingdom: therapists’ practices. Int J Lang Commun Disord 2011, 46:189-201.
• [9]Ramig LO, Countryman S, Thompson LL, Horii Y: Comparison of two forms of intensive speech treatment for Parkinson disease. J Speech Hear Res 1995, 38:1232-1251.
• [10]Herd CP, Tomlinson CL, Deane KH, Brady MC, Smith CH, Sackley CM, Clarke CE: Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease. Cochrane Db Syst Rev 2012., 8CD002814
• [11]Ramig LO, Sapir S, Fox C, Countryman S: Changes in vocal loudness following intensive voice treatment (LSVT®) in individuals with Parkinson’s disease: a comparison with untreated patients and normal age-matched controls. Mov Disord 2001, 16:79-83.
• [12]Robertson SJ, Thomson F: Speech therapy in Parkinson's Disease: a study of the efficacy and long term effects of intensive treatment. Int J Lang Commun Disord 1984, 19:213-224.
• [13]Johnson JA, Pring TR: Speech therapy and Parkinson’s disease: a review and further data. Br J Disord Commun 1990, 25:183-194.
• [14]Medical Research Council: Developing and evaluating complex interventions: New guidance. London: MRC; 2008.
• [15]PD COMM: Trial documentation. [http://www.birmingham.ac.uk/research/activity/mds/trials/bctu/trials/pd/pdcomm/investigators/documentation.aspx webcite]
• [16]Lancaster GA, Dodd S, Williamson PR: Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract 2004, 10:307-312.
• [17]Gibb WR, Lees AJ: The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 1988, 51:745-752.
• [18]Ramig LO: Intensive voice treatment (LSVT®) for patients with Parkinson’s disease: a 2 year follow up. J Neurol Neurosurg Psychiatry 2001, 71:493-498.
• [19]El Sharkawi A, Ramig L, Logemann JA, Pauloski BR, Rademaker AW, Smith CH, Pawlas A, Baum S, Werner C: Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT®): a pilot study. J Neurol Neurosurg Psychiatry 2002, 72:31-36.
• [20]Spielman J, Ramig LO, Mahler L, Halpern A, Gavin WJ: Effects of an extended version of the Lee Silverman voice treatment on voice and speech in Parkinson’s disease. Am J Speech Lang Pathol 2007, 16:95-107.
• [21]Scott S, Caird FI: Speech therapy for Parkinson’s disease. J Neurol Neurosurg Psychiatry 1983, 46:140-144.
• [22]Schulz GM, Grant MK: Effects of speech therapy and pharmacologic and surgical treatments on voice and speech in Parkinson’s disease: a review of the literature. J Commun Disord 2000, 33:59-88.
• [23]Jacobson BH, Johnson A, Grywalski C, Silbergleit A, Jacobson G, Benninger MS, Newman CW: The voice handicap index (VHI): development and validation. Am J Speech Lang Pathol 1997, 6:66-70.
• [24]Yorkston KM, Beukelman DR: Assessment of intelligibility of dysarthric speech. Austin, Texas: Pro-Ed; 1981.
• [25]Goodglass H, Kaplan E, Barresi B: Boston diagnostic aphasia examination. Philadelphia, PA: Lippincott Williams and Wilkins; 2001.
• [26]Peto V, Jenkinson C, Fitzpatrick R: PDQ-39: a review of the development, validation and application of a Parkinson’s disease quality of life questionnaire and its associated measures. J Neurol 1998, 245(Suppl 1):S10-S14.
• [27]Hogikyan ND, Sethuraman G: Validation of an instrument to measure voice-related quality of life (V-RQOL). J Voice 1999, 13:557-569.
• [28]Hartelius L, Elmberg M, Holm R, Lovberg AS, Nikolaidis S: Living with dysarthria: evaluation of a self-report questionnaire. Folia Phoniatr Logop 2008, 60:11-19.
• [29]Jenkinson C, Dummett S, Kelly L, Peters M, Dawson J, Morley D, Fitzpatrick R: The development and validation of a quality of life measure for the carers of people with Parkinson’s disease (the PDQ-Carer). Parkinsonism Relat Disord 2012, 18:483-487.
• [30]EuroQol Group: EuroQol–a new facility for the measurement of health-related quality of life. Health Policy 1990, 16:199-208.
• [31]Grewal I, Lewis J, Flynn T, Brown J, Bond J, Coast J: Developing attributes for a generic quality of life measure for older people: preferences or capabilities? Soc Sci Med 2006, 62:1891-1901.
• [32]Coast J, Flynn TN, Natarajan L, Sproston K, Lewis J, Louviere JJ, Peters TJ: Valuing the ICECAP capability index for older people. Soc Sci Med 2008, 67:874-882.